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Abstract. The presence of mutations in the KRAS gene is a 
predictor of a poor clinical response to EGFR-targeted agents 
in patients affected by colorectal cancer (CRC), but its signifi-
cance as a global prognostic factor remains unclear. The aim 
of the present study was to evaluate the impact of the KRAS 
mutational status on time to first metastasis (TTM) and overall 
survival (OS) in a cohort of Sardinian CRC patients. A total 
of 551 patients with metastatic CRC at the time of enrol-
ment were included. Clinical and pathological features of the 
disease, including follow-up information, were obtained from 
medical records and cancer registry data. For mutational anal-
ysis formalin‑fixed paraffin‑embedded tissue samples were 
processed using a standard protocol. The coding sequence 
and splice junctions of exons 2 and 3 of the KRAS gene were 
screened for mutations by direct automated sequencing. 
Overall, 186 KRAS mutations were detected in 183/551 (33%) 
patients: 125 (67%) were located in codon 12, 36 (19%) in 
codon 13, and 18 (10%) in codon 61. The remaining mutations 
(7; 4%) were detected in uncommonly‑affected codons. No 
significant correlation between KRAS mutations and gender, 
age, anatomical location and stage of the disease at the time 
of diagnosis was identified. Furthermore, no prognostic value 
of KRAS mutations was found considering either TTM or OS. 
When patients were stratified by KRAS mutational status and 
gender, males were significantly associated with a longer TTM. 
The results of the present study indicate that KRAS mutation 
correlated with a slower metastatic progression in males with 
CRC from Sardinia, irrespective of the age at diagnosis and 
the codon of the mutation.
Introduction
Colorectal cancer (CRC) is the third most common neoplastic 
disease in males, after lung and prostate cancer, and the second 
in females after breast cancer; furthermore, it is the fourth most 
frequent neoplastic cause of mortality after lung, stomach, and 
liver cancer (1). Excellent results have been obtained in the 
management of non-invasive and early-stage invasive disease 
in recent times, particularly due to improvements in multidis-
ciplinary endoscopic, surgical, radiotherapeutic and medical 
oncology protocols. Conversely, progression in the setting of 
advanced and/or metastatic disease have been less consistent, 
and relative survival rates remain low (1‑3). The role of tumour 
genetics in this setting is extremely important, particularly 
in the development of novel therapeutic strategies, based on 
specific molecular targets.
The most relevant results of ‘targeted therapies’ have 
been obtained thanks to the comprehension of the patho-
physiological mechanisms involving the epidermal growth 
factor receptor (EGFR)-RAS cascade (4). The EGFR is a 
trans-membrane protein for epidermal growth factor that medi-
ates its functions through the activation of the RAS protein 
family members (HRAS, KRAS, and NRAS) (4). Activated 
RAS proteins promote cell proliferation through a number of 
mechanisms, including constitutive stimulation of mitogen 
activated protein‑kinases (MAPK) (4). EGFR‑targeted agents 
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that compete with EGF for binding the receptor have been 
employed in clinical practice, in order to inhibit cell prolif-
eration (5). Oncogenic RAS activation is a result of specific 
mutations into the kinase regions of the genes, producing a 
constitutive induction of the phosphorylating function of the 
RAS proteins, which in turn promotes neoplastic proliferation 
and drastically reduces the effect of anti-EGFR therapies (5,6). 
Indeed, mutations in KRAS have been extensively demon-
strated to act as a predictor of the absence of clinical response 
to EGFR-targeted agents (7‑9). Nevertheless, the significance 
of KRAS mutation as a global prognostic factor of disease 
progression and survival in patients with colorectal cancer is 
not clear. Previous studies have reported a statistically signifi-
cant reduction in disease free (DFS) and overall survival (OS) 
in the presence of KRAS mutations (10,11). Nevertheless, such 
findings were not confirmed in another study (12). The aim of 
the present study was to evaluate the significance of the KRAS 
mutational status in terms of time to first metastasis (TTM) 
and OS in a cohort of Sardinian patients with CRC.
Materials and methods
Study population. A total of 551 patients with a histologically 
proven diagnosis of metastatic CRC at the time of enrolment, 
who were treated and followed-up at healthcare institutions 
across Sardinia, were included into the study. To avoid any bias, 
CRC patients were consecutively collected from March 2009 
to July 2014; they were included regardless of age at diagnosis 
and disease characteristics. Cases associated with syndromic 
colorectal polyposis were excluded.
Sardinian origin was ascertained in all cases through 
genealogical studies; for all patients, place of birth of their 
parents and grandparents was assessed in order to assign 
their geographical origin within the island. Clinical and 
pathological features for the assessment of the disease stage 
at diagnosis as well as of the onset age and tumor anatomical 
location were confirmed by medical records and/or pathology 
reports. Follow-up and prognostic information were obtained 
from clinical records at the institutions participating to the 
study and the records from the local cancer registry. The local 
cancer registry collects data on neoplastic diseases affecting 
inhabitants in north Sardinia, through the local hospitals and 
health care services as with other registries (e.g., death regis-
tries), and forms part of a wider network of tumour registries 
coordinated by the Italian Association for Tumour Registries 
(Associazione Italiana Registri Tumori, AIRTUM). 
All patients gave written informed consent for KRAS muta-
tion analysis prior to tissue sample collection. The study was 
reviewed and approved by the ethics committee of the Local 
Health Agency of Sassari (Sassari, Italy).
KRAS mutational analysis. Formalin‑fixed paraffin embedded 
tissue samples from CRC patients were obtained from the 
archives of the Institutes and Services of Pathology partici-
pating in the study. Tissue samples were estimated to contain at 
least 70% neoplastic cells by light microscopy. Subsequently, 
all tumor tissues were processed at the laboratory of the 
Institute of Biomolecular Chemistry of Sassari; genomic DNA 
was isolated from tissue sections using a standard protocol 
and DNA quality assessed for each specimen. In particular, 
paraffin was removed from formalin‑fixed paraffin‑embedded 
(FFPE) samples by treatment with Bio‑Clear (Bio‑optica, 
Milan, Italy) and DNA was purified using the QIAamp DNA 
FFPE Tissue kit (QIAGEN Inc., Valencia, CA, USA).
The coding sequence and splice junctions of exons 2, 3, 
and 4 of the KRAS gene (where all pathogenic mutations occur), 
were screened for mutations by direct automated sequencing. 
Briefly, polymerase chain reaction (PCR) was performed on 
25‑50 ng of isolated genomic DNA in a 9,700 Thermal cycler 
(Life Technologies/ThermoFisher Scientific, Inc., Waltham, 
MA, USA); all PCR products were directly sequenced using 
an automated fluorescence‑based cycle sequencer (ABIPRISM 
3130, Life Technologies, ThermoFisher Scientific Inc.), as 
previously described (13). Primer sequences and protocols for 
PCR‑based assays were designed and optimized in our labora-
tory; they are available upon request.
Statistical analysis. Statistical analysis was performed using 
the statistical package SPSS version 7.5 for Windows (SPSS, 
Inc., Chicago, IL, USA) and Pearson's Chi‑Squared test. 
Descriptive analysis for qualitative variables was conducted 
using proportions. P≤0.05 was considered to indicate a statisti-
cally significant difference. Furthermore, a Cox proportional 
hazards regression model using the Newton-Raphson algorithm 
was used to determine the impact of the following variables on 
survival: Gender, age, KRAS status and mutation codons.
Results
Paraffin‑embedded tumour tissues from a total of 551 patients 
with invasive CRC and originating from Sardinia island were 
screened for mutations in the KRAS gene. The median age of 
the patients was 65 years (range, 32‑87 years), with a prepon-
derance of males (328 men; 59.5%). Considering the location 
of the primary tumour, the left colon was most frequently 
involved [left colon, 263 (48%); right‑transverse colon, 
181 (29%); rectum, 107 (19%)] (Table I). Considering the 
disease stage at the time of diagnosis, the majority of patients 
presented without distant metastases [55%; AJCC stages II and 
III, 162 (29.4%) and 140 (25.4%), respectively] (Table I).
The full coding sequences and intron‑exon junctions of the 
KRAS gene were sequenced in the entire series of 551 CRC 
patients. Overall, KRAS mutations were detected in 183 (33%) 
patients; 3 patients presented with coexistence of 2 KRAS muta-
tions in the same primary tumor tissue (Table II). In terms of the 
gene positions of the identified 186 KRAS mutations, 125 (67%) 
of the mutations were located in codon 12, 36 (19.4%) were 
located in codon 13, and 18 (9.7%) were in codon 61 (Fig. 1). 
The remaining mutations (7; 3.8%) were detected in uncom-
monly-affected codons of the KRAS gene (Table II and Fig. 2). 
All KRAS mutations detected in the present study have been 
previously reported in the Human Gene Mutation Database 
(HGMD) of the Institute of Medical Genetics in Cardiff 
(http://archive.uwcm.ac.uk) and in the Catalogue Of Somatic 
Mutations In Cancer (COSMIC) of the Wellcome Trust Sanger 
Institute (http://www.sanger.ac.uk/genetics/CGP/cosmic/).
No statistically significant correlations were identified 
between the presence of KRAS mutations and gender, age at 
diagnosis, anatomical location of primary CRC, and AJCC 
stage of the disease at the time of diagnosis (Table I).
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Using the Cox proportional hazards model, no prognostic 
values of KRAS mutations were identified for the TTM [Odds 
Ratio (OR) 1.18, 95% CI 0.81‑1.72, P=0.198] or OS (OR 1.28, 
95% CI 0.87‑1.90, P=0.107) (Table IIIA). When patients 
were stratified by both KRAS mutational status and gender, 
significantly improved TTM was observed for KRAS-mutated 
male cases (OR 1.58, 95% CI 0.96‑2.60, P=0.035) (Table IIIA; 
Fig. 3A). Conversely, no difference in OS was observed 
between the two genders according to the occurrence of KRAS 
mutations (Fig. 3B). Considering the gene positions of the 
identified KRAS mutations, no correlation with both the TTM 
(Table IIIB) and OS (data not shown) was observed.
Discussion
The KRAS proto-oncogene encodes a guanosine triphos-
phate (GTP)/guanosine diphosphate (GDP) binding protein 
(21 kDa), which regulates cell responses to a number of 
extracellular stimuli (14). Activating mutations in KRAS are 
dominant and generally appear in an early stage of CRC carci-
nogenesis (early-intermediate adenoma), maintaining a stable 
incidence in higher stages (late adenomas and carcinomas). 
Approximately 30‑50% of CRC patients have KRAS mutations, 
and they are associated with poor responsiveness to anti-EGFR 
antibody therapies (7-10,15). In the present study, 33% of the 
patients with CRC harboured a mutation in the KRAS gene. In 
accordance with previous reports, no statistically significant 
differences in the distribution of these mutations between 
genders, ages, disease locations, and stages were found in our 
cohort (10). In addition, the mutation sites within the gene were 
similar to those widely reported, with the codons 12 and 13 
affected in ~80% of cases. Notably, 7 mutations were identi-
fied in uncommonly‑affected codons (Table II). In total, 6 of 
these mutations were single base substitutions and one was an 
insertion between codons 12 and 13 (c.35_36insAGCTGG). 
KRAS insertions have been sporadically reported among CRC 
Table II. Unusual KRAS mutations found in the cohort of the present study.
Amino acid mutation DNA mutation No. cases
Mutations in uncommon codons  
  p.G12_G13insAG c.35_36insAGCTGG 1
  p.E49K c.145G>A 1
  p.A59E c.176C>A 1
  p.K117N c.351A>T 1
  p.A146T c.436G>A 3
Coexistent multiple mutations
  p.G12D+p.Q61H c.35_36GT>AC + c.183A>C 1
  p.G12D+p.Q61L c.35_36GT>AC + c.182A>T 1
  p.G13V+p.Q61H c.38G>T + c.183A>C 1
Table I. Distribution of mutations according to the characteristics of colorectal cancer patients.
Characteristic No. (N=551) KRAS mutations (%) P
Gender   
  Male 328 103 (31) 0.654
  Female 223 80 (36) 
Tumor site   
  Right‑transverse colon 181 62 (34) 0.933
  Left colon 263 85 (32) 
  Rectum 107 36 (34) 
Disease stage at diagnosis   
  Stage II 162 50 (31) 0.247
  Stage III 140 47 (34) 
  Stage IV 249 86 (35) 
Age, years   
  <50 51 18 (35) 0.788
  50‑59 122 48 (39) 
  60‑69 200 64 (32) 
  70+ 178 53 (30) 
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patients; overall, biological and clinical significance of such 
mutations is yet to be defined (16).
Despite knowledge of the effect of KRAS mutations in 
predicting lack of response to anti-EGFR therapy, the global 
impact of such mutations on OS and DFS in CRC patients 
remains controversial. In 1994, Tanaka et al (17) published the 
first valuable article on such a topic. The authors examined 
a cohort of 15 KRAS mutations occurring in 62 Japanese 
patients using an oligonucleotide hybridization technique, 
and found that KRAS mutation was an independent prog-
nostic factor in a multivariate analysis (17). In the same 
year, Morrin et al (18) published a less extensive study on 
52 CRC patients with 14 KRAS mutations, without evidence 
of any prognostic impact. One year later, Bennett et al (19) 
published their series of 157 Dukes' stage B CRCs with muta-
tions in codon 12, which were analysed by PCR and direct 
sequencing. The authors failed to demonstrate a predictive role 
for survival of KRAS mutations by log rank and multivariate 
analysis (19). Lee et al (20) subsequently reported a series of 
64 Chinese patients; 38 patients were Dukes' stage A and B, 
and 26 patients were Dukes' stage C and D (20). Log rank tests 
identified that KRAS gene mutation and Dukes' stage were 
associated with patients' survival; furthermore, patients with 
KRAS mutations were found to have shorter survival times 
into the subgroup with Dukes' stage A and B, but not in that 
with stages C and D (20). Pricolo et al (21) published their 
series on 70 Dukes' stage C patients analysed by topographic 
genotyping, and found a 36% KRAS mutations that did not 
affect significantly the risk of mortality or the 5‑year survival 
rate. In 1998, Kressner et al (22) published their results on 
a series of 62 KRAS mutations found by temporal tempera-
ture gradient gel electrophoresis among 191 Swedish CRC 
patients; again, KRAS mutations had no relevant prognostic 
importance (22). Conversely, Andreyev et al (23) performed 
the RASCAL study, a large cohort collaborative report which 
indicated that KRAS mutations-especially those of codon 12 
were associated with increased risk of relapse or mortality. 
More specifically, the subsequent RASCAL II study, which 
involved 3,498 patients with CRC, indicated that only the 
Figure 1. Types and frequencies of the mutations observed in the cohort.
Figure 2. Mutations in uncommonly‑affected codons of the KRAS gene 
found in the cohort.
Figure 3. (A) Time to first metastasis and (B) overall survival according to 
gender in patients harboring KRAS mutations.
  A
  B
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substitution of glycine to valine on codon 12 had a significant 
influence on OS, particularly among patients with Dukes' 
stage C carcinomas (10). These studies did not indicate any 
prognostic role for mutations in codon 13 of the KRAS gene. 
Certain authors consider that the prognostic value for the 
KRASG12V mutation in the RASCAL study may represent the 
result of methodological limitations due to the retrospective 
recollection of patients enrolled in different studies using 
3 different mutational tests, and possible nonrandom systemic 
errors that may affect meta-analysis of such datasets (24).
In 2000, Samowitz et al (25) published their results on a large 
cohort including 100 KRAScodon 13 mutations identified by PCR 
and direct sequencing‑in 1,413 CRC patients from California 
and Utah. The authors found that generally KRAS mutations 
were not associated with increased cancer-associated mortality 
in their cohort; nevertheless, mutations in codon 13 were 
associated with a 40% greater likelihood of dying, although 
the significance of such finding was borderline when adjusted 
for age and disease stage (25). Other valuable studies on the 
prognostic significance of KRAS mutations in CRC patients 
were performed during the 2000s; the most relevant series 
were those of Ogino et al (26) in the USA, Zlobec et al (27) in 
Switzerland, Winder et al (28) in Austria, and Bazan et al (29) 
in Italy. Ogino and collegues performed an evaluation of the 
independent effect of the CpG island methylator phenotype 
(CIMP), microsatellite instability (MSI), KRAS and BRAF 
mutations on the prognosis of 649 patients with I‑IV stage 
CRC. The study did not identify a relevant role of the KRAS 
mutations on prognosis, but the authors provided evidence that 
CIMP‑high appears to be an independent predictor of a low 
CRC‑specific mortality, while BRAF mutations are associ-
ated with a high CRC‑specific mortality (26). By contrast, in 
their combined analysis of specific KRAS gene alterations, 
BRAFV600E status, and MSI, Zlobec et al (27) found that 
specific KRAS mutations act as informative prognostic factors 
in both sporadic and hereditary CRC; an algorithm including 
all these alteration may identify sporadic CRC patients with 
poor clinical outcome. Winder et al (28) in their Austrian 
series of 342 cases were the first to report an improved OS 
in patients with KRAScodon 13 mutations compared to those 
with wild-type genes, further suggesting that different types 
of KRAS mutations may be differently associated with OS 
in patients with CRC (28). Finally, a multivariate analysis by 
Bazan et al (29) in a series of 160 cases found that KRAScodon 13 
mutations were associated with poorer OS but not DFS (29).
It is evident that the global prognostic impact of KRAS 
mutations in patients with colorectal cancer remains unclear. 
The discrepancy of results among the studies mentioned 
Table III. Correlation between KRAS mutational status and survival.
A, KRAS mutation status in toto
 Confidence interval
 ----------------------------------------------------------
Parameter Odds Ratio Lower Upper P‑value
TTM
  KRAS status 1.187 0.816 1.726 0.198
  Female and KRAS status 0.799 0.444 1.439 0.254
  Male and KRAS status 1.583 0.962 2.606 0.035
OS
  KRAS status 1.286 0.874 1.903 0.107
  Female and KRAS status 1.151 0.825 2.766 0.100
  Male and KRAS status 1.141 0.679 1.935 0.345
B, KRAS codon‑specific mutations
 Confidence interval
 ------------------------------------------------------------
Parameter P‑value Hazard ratio Lower Upper
TTM
  Gender 0.011 0.728 0.569 0.931
  Age at diagnosis 0.473 1.161 0.771 1.750
  Codon 12 mutations 0.907 1.037 0.559 1.924
  Codon 13 mutations 0.861 1.045 0.634 1.721
  Other codon mutations 0.806 1.076 0.598 1.935
TTM, time to first metastasis; OS, overall survival.
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may be explained on the basis of the relevant number of 
confounding and heterogeneity factors. The most frequent are: 
a) Heterogeneity of the study populations; b) discrepancies 
in study design and methodology; c) strategies for detecting 
KRAS mutations (including type of tissue samples i.e., primary 
or metastatic tumours); d) presence of underlying predisposing 
conditions (i.e. ulcerative colitis); e) variability of the staging 
systems (Dukes, AJCC, different editions); and f) clinical 
management and treatments employed.
Ren et al (30) have recently published a well-designed 
review and meta-analysis on the impact of KRAS mutations 
on OS in CRC patients, with the aim to reduce biases as 
those mentioned above (30). The authors performed a careful 
selection of 23 articles published from 1992, including 25 sets 
of data with 4,687 patients and 1,364 (29%) KRAS-mutated 
cases. Among them, 9 indicated that KRAS mutations were 
associated with worse prognosis, 15 failed to demonstrate any 
statistically significant association between such mutations 
and prognosis, and, finally, one data set identified an improved 
survival rate for patents with CRC and KRAS mutations (30). 
Globally, the authors found that KRAS mutations were not 
associated with CRC prognosis, either before or after adjust-
ment for the effect of publication bias. Notably, the authors 
found that KRAS mutations in codon 13, and the technique 
of mutation detection (PCR‑RFLP or PCR‑SSCP, followed 
by sequencing) were associated with poorer OS; nevertheless, 
the authors considered that sample size may have not enough 
statistical power to accurately detect the association between 
KRAS mutations and survival (30).
In the present study, a clear association between occurrence 
of KRAS mutations and TTM or OS was not demonstrated in 
the entire series of 551 CRCs. When patients were stratified 
by both KRAS mutational status and gender, again, no signifi-
cant differences in OS were identified, but a significantly 
improved TTM was observed for KRAS-mutated male cases. 
This finding is particularly notable, as the present study is the 
first to describe it in a series with a consistent number of CRC 
patients. Furthermore, TTM was determined which in our 
opinion better describes the biological events of CRC evolu-
tion in comparison with disease free survival (DFS) which 
better describes the impact of therapies on the progression of 
the disease.
On this regard, Samowitz et al (25) suggested that male 
patients are more likely to present transition mutations and 
G→A mutations due to different lifestyle factors, including 
alcohol and tobacco use, or dietary habits, which men and 
women are differently exposed to. In addition, the hormonal 
status has been involved in the pathogenesis of CRC through 
its impact on bile production and composition, bowel transit 
times, and bacterial metabolism (25,31). A smaller increase in 
mortality in patients with transition mutations has been previ-
ously reported, while the variant with the higher likelihood of 
mortality was the G→A mutation at the codon 13 (25). The 
latter finding was also observed by Cerrottini et al (32). These 
data evidence that male patients may harbour less aggressive 
KRAS mutations, and this may explain the findings of the 
present study; nevertheless, it is not clear why this effect is 
limited to the initial progression as metastatic disease and 
does not affect OS. Unfortunately, the issue is not adequately 
studied in the current literature, and further well-designed 
studies are necessary to improve the understanding of such 
a specific prognostic variation in subgroups of patients with 
KRAS mutations.
The data presented in the current study suggest that 
KRAS mutations are not generally associated with TTM and 
OS in patients with CRC. Nevertheless, an improved TTM 
was observed in male patients with CRC harbouring KRAS 
mutations. Such a finding may be associated with the specific 
types of KRAS mutations observed in males and females as 
consequence of exposure to different lifestyle factors. Further 
well‑designed studies are necessary to confirm such findings.
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